A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
A sustainable business model based on innovation and ... - Roche
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Top 10 Oncology Products<br />
Sales <strong>and</strong> market shares in seven major markets in 2007<br />
50%<br />
40%<br />
Avastin<br />
$2,651m<br />
CAGR, 2006-07<br />
30%<br />
20%<br />
10%<br />
0%<br />
Herceptin<br />
$2,653m<br />
Erbitux<br />
Taxotere<br />
$1,040m<br />
Arimidex<br />
$1,837m<br />
$1,364m<br />
Gleevec<br />
$1,990m<br />
Gemzar<br />
Lupr<strong>on</strong><br />
Rituxan<br />
$1,156m<br />
$1,411m<br />
Eloxatin<br />
$3,216m<br />
$1,964m<br />
0% 2% 4% 6% 8% 10% 12%<br />
-10%<br />
Bubble size represents 2007 sales<br />
Market share, 2007<br />
Source: Datam<strong>on</strong>itor, MIDAS Sales Data, IMS Health, April 2008, Copyright ©, reprinted<br />
with permissi<strong>on</strong><br />
<strong>Roche</strong>/Genetech’s MabThera, Herceptin <strong>and</strong> Avastin<br />
DMHC2416: Commercial Insight: Top 20 Therapy Cancer Br<strong>and</strong>s (08/2008)<br />
dominate the current cancer br<strong>and</strong>s market<br />
37
Change language